Pretubulysin is a natural product that is found in strains of myxobacteria in only minute amounts. It represents the first enzyme-free intermediate in the biosynthesis of tubulysins and undergoes post-assembly acylation and oxidation reactions. Pretubulysin inhibits the growth of cultured mammalian cells, as do tubulysins, which are already in advanced preclinical development as anticancer and antiangiogenic agents. The mechanism of action of this highly potent compound class involves the depolymerization of microtubules, thereby inducing mitotic arrest. Supply issues with naturally occurring derivatives can now be circumvented by the total synthesis of pretubulysin, which, in contrast to tubulysin, is synthetically accessible in gram-scale quantities. We show that the simplified precursor is nearly equally potent to the parent compound. Pretubulysin induces apoptosis and inhibits cancer cell migration and tubulin assembly in vitro. Consequently, pretubulysin appears to be an ideal candidate for future development in preclinical trials and is a very promising early lead structure in cancer therapy.
References
[1]
Harvey AL (2008) Natural products in drug discovery. Drug Disc Tod 13: 894–901.
[2]
Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70: 461–477.
[3]
Li JW, Vederas JC (2009) Drug discovery and natural products: end of an era or an endless frontier? Science 325: 161–165.
Fenical W, Jensen PR (2006) Developing a new resource for drug discovery: marine actinomycete bacteria. Nat Chem Biol 2: 666–673.
[6]
Garcia R, Gerth K, Stadler M, Dogma IJ Jr, Müller R (2010) Expanded phylogeny of myxobacteria and evidence for cultivation of the ‘unculturables’. Mol Phylogenet Evol 57: 878–887.
[7]
Wenzel SC, Müller R (2009) The biosynthetic potential of myxobacteria and their impact in drug discovery. Curr Opin Drug Discov Devel 12: 220–230.
[8]
Gerth K, Pradella S, Perlova O, Beyer S, Müller R (2003) Myxobacteria: proficient producers of novel natural products with various biological activities–past and future biotechnological aspects with the focus on the genus Sorangium. J Biotechnol 106: 233–253.
[9]
Weissman KJ, Müller R (2010) Myxobacterial secondary metabolites: bioactivities and modes-of-action. Nat Prod Rep 27: 1276–1295.
[10]
Newman DJ, Cragg GM (2012) Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010. J Nat Prod 75: 311–335.
[11]
Butler MS (2008) Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep 25: 475–516.
[12]
Cragg GM, Newman DJ (2005) Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72–79.
[13]
Dumontet C, Jordan MA (2010) Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9: 790–803.
[14]
H？fle G, Bedorf N, Steinmetz H, Schomburg D, Gerth K, et al. (1996) Epothilon A und B – neuartige, 16gliedrige Makrolide mit cytotoxischer Wirkung: Isolierung, Struktur im Kristall und Konformation in L？sung. Angew Chem 108: 1671–1673.
[15]
Jansen R, Irschik H, Reichenbach H, Wray V, H？fle G (1994) Antibiotics from Gliding Bacteria, LIX. Disorazoles, Highly Cytotoxic Metabolites from the Sorangicin-Producing Bacterium Sorangium Cellulosum, Strain So ce12. Liebigs Ann Chem 759–773.
[16]
Sasse F, Steinmetz H, Heil J, H？fle G, Reichenbach H (2000) Tubulysins, new cytostatic peptides from myxobacteria acting on microtubuli. Production, isolation, physico-chemical and biological properties. J Antibiot (Tokyo) 53: 879–885.
[17]
Irschik H, Jansen R, Gerth K, H？fle G, Reichenbach H (1995) Chivosazol A, a new inhibitor of eukaryotic organisms isolated from myxobacteria. J Antibiot (Tokyo) 48: 962–966.
[18]
Kunze B, Jansen R, Sasse F, H？fle G, Reichenbach H (1995) Chondramides A approximately D, new antifungal and cytostatic depsipeptides from Chondromyces crocatus (myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo) 48: 1262–1266.
[19]
Sasse F, Steinmetz H, H？fle G, Reichenbach H (1993) Rhizopodin, a new compound from Myxococcus stipitatus (myxobacteria) causes formation of rhizopodia-like structures in animal cell cultures. Production, isolation, physico-chemical and biological properties. J Antibiot (Tokyo) 46: 741–748.
[20]
D？mling A, Richter W (2005) Myxobacterial epothilones and tubulysins as promising anticancer agents. Mol Divers 9: 141–147.
[21]
Hopkins CD, Wipf P (2009) Isolation, biology and chemistry of the disorazoles: new anti-cancer macrodiolides. Nat Prod Rep 26: 585–601.
[22]
Conlin A, Fornier M, Hudis C, Kar S, Kirkpatrick P (2007) Ixabepilone. Nat Rev Drug Discov 6: 953–954.
[23]
Sandmann A, Sasse F, Müller R (2004) Identification and analysis of the core biosynthetic machinery of tubulysin, a potent cytotoxin with potential anticancer activity. Chem Biol 11: 1071–1079.
[24]
Ullrich A, Chai Y, Pistorius D, Elnakady YE, Herrmann JE, et al. (2009) Pretubulysin, a potent and chemically accessible tubulysin precursor from Angiococcus disciformis. Angew Chem Int Ed Engl 48: 4422–4425.
[25]
Peltier HM, McMahon JP, Patterson AW, Ellman JA (2006) The total synthesis of tubulysin D. J Am Chem Soc 128: 16018–16019.
[26]
Neri D, Fossati G, Zanda M (2006) Efforts toward the total synthesis of tubulysins: new hopes for a more effective targeted drug delivery to tumors. ChemMedChem 1: 175–180.
[27]
Ullrich A, Herrmann J, Müller R, Kazmaier U (2009) Synthesis and Biological Evaluation of Pretubulysins and Derivatives. Eur J Org Chem 36: 6367–6378.
[28]
Wang Z, McPherson PA, Raccor BS, Balachandran R, Zhu G, et al. (2007) Structure-activity and high-content imaging analyses of novel tubulysins. Chem Biol Drug Des 70: 75–86.
[29]
Kubicek K, Grimm SK, Orts J, Sasse F, Carlomagno T (2010) The tubulin-bound structure of the antimitotic drug tubulysin. Angew Chem Int Ed Engl 49: 4809–4812.
Khalil MW, Sasse F, Lünsdorf H, Elnakady YA, Reichenbach H (2006) Mechanism of action of tubulysin, an antimitotic peptide from myxobacteria. ChemBioChem 7: 678–683.
[32]
Bhalla K, Ibrado AM, Tourkina E, Tang C, Mahoney ME, et al. (1993) Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 7: 563–568.
[33]
Wang TH, Wang HS, Soong YK (2000) Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 88: 2619–2628.
[34]
Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ (1993) Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75: 241–251.
[35]
Blagosklonny MV (2001) Unwinding the loop of Bcl-2 phosphorylation. Leukemia 15: 869–874.
[36]
Yamaguchi H, Wang HG (2002) Bcl-XL protects BimEL-induced Bax conformational change and cytochrome C release independent of interacting with Bax or BimEL. J Biol Chem 277: 41604–41612.
[37]
Yamaguchi H, Paranawithana SR, Lee MW, Huang Z, Bhalla KN, et al. (2002) Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res 62: 466–471.
[38]
Weiderhold KN, Randall-Hlubek DA, Polin LA, Hamel E, Mooberry SL (2006) CB694, a novel antimitotic with antitumor activities. Int J Cancer 118: 1032–1040.
[39]
Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, et al. (1997) Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked. Science 275: 1129–1132.
[40]
Ola MS, Nawaz M, Ahsan H (2011) Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem 351: 41–58.
[41]
Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, et al. (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37–43.
[42]
Virág L, Szabó C (2002) The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54: 375–429.
[43]
Irschik H, Jansen R, Gerth K, H？fle G, Reichenbach H (1995) Disorazol A, an efficient inhibitor of eukaryotic organisms isolated from myxobacteria. J Antibiot (Tokyo) 48: 31–35.
[44]
Elnakady YA, Sasse F, Lünsdorf H, Reichenbach H (2004) Disorazol A1, a highly effective antimitotic agent acting on tubulin polymerization and inducing apoptosis in mammalian cells. Biochem Pharmacol 67: 927–935.
[45]
Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, et al. (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55: 2325–2333.
[46]
Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM (2000) Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem 275: 9390–9395.
[47]
Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM, et al. (2010) Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res 16: 4532–4542.
[48]
Palmer TD, Ashby WJ, Lewis JD, Zijlstran A (2011) Targeting tumor cell motility to prevent metastasis. Adv Drug Del Rev 63: 568–581.
[49]
van Zijl F, Krupitza G, Mikulits W (2011) Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res 728: 23–34.
[50]
Steinmetz H, Glaser N, Herdtweck E, Sasse F, Reichenbach H, et al. (2004) Isolation, crystal and solution structure determination, and biosynthesis of tubulysins–powerful inhibitors of tubulin polymerization from myxobacteria. Angew Chem Int Ed Engl 43: 4888–4892.
[51]
Burkhart JL, Müller R, Kazmaier U (2011) Syntheses and Evaluation of Simplified Pretubulysin Analogues. Eur J Org Chem 16: 3050–3059.
[52]
Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ (1999) In Vivo Selection and Characterization of Metastatic Variants from Human Pancreatic Adenocarcinoma by Using Orthotopic Implantation in Nude Mice. Neoplasia 1: 50–62.
[53]
Gong J, Traganos F, Darzynkiewicz Z (1994) A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 218: 314–319.
[54]
Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271–279.
[55]
Sloboda RD, Dentler WL, Rosenbaum JL (1976) Microtubule-associated proteins and the stimulation of tubulin assembly in vitro. Biochemistry 15: 4497–4505.
[56]
Gaskin F, Cantor CR, Shelanski ML (1974) Turbidimetric studies of the in vitro assembly and disassembly of porcine neurotubules. J Mol Biol 89: 737–755.
